DexCom, Inc. (NASDAQ:DXCM)‘s stock had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies in a report issued on Monday. They presently have a $78.00 price target on the medical device company’s stock. Piper Jaffray Companies’ price target indicates a potential upside of 15.28% from the company’s previous close.

DXCM has been the topic of several other research reports. Jefferies Group LLC decreased their price objective on DexCom to $91.00 and set a “buy” rating on the stock in a report on Tuesday, May 9th. Robert W. Baird restated a “neutral” rating and set a $79.00 price objective on shares of DexCom in a report on Thursday, February 16th. Oppenheimer Holdings Inc. restated a “buy” rating on shares of DexCom in a report on Wednesday, March 22nd. B. Riley restated a “buy” rating and set a $94.00 price objective on shares of DexCom in a report on Monday, February 13th. Finally, Canaccord Genuity decreased their price objective on DexCom from $95.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, May 3rd. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $90.44.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Shares of DexCom (NASDAQ:DXCM) opened at 67.66 on Monday. The company’s 50-day moving average price is $75.47 and its 200-day moving average price is $73.57. The company’s market cap is $5.84 billion. DexCom has a 12 month low of $57.68 and a 12 month high of $96.38.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Tuesday, May 2nd. The medical device company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.06. DexCom had a negative return on equity of 23.61% and a negative net margin of 10.64%. The business had revenue of $142.30 million for the quarter, compared to analysts’ expectations of $143.94 million. Equities analysts forecast that DexCom will post ($0.68) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “DexCom, Inc. (DXCM) Earns “Overweight” Rating from Piper Jaffray Companies” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/05/22/dexcom-inc-dxcm-earns-overweight-rating-from-piper-jaffray-companies.html.

In other DexCom news, CEO Kevin R. Sayer sold 8,649 shares of the firm’s stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $68.39, for a total value of $591,505.11. Following the transaction, the chief executive officer now directly owns 347,329 shares of the company’s stock, valued at $23,753,830.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jacob Steven Leach sold 21,317 shares of the firm’s stock in a transaction dated Tuesday, March 14th. The shares were sold at an average price of $77.63, for a total value of $1,654,838.71. The disclosure for this sale can be found here. Insiders sold 132,202 shares of company stock worth $10,102,405 over the last three months. 2.80% of the stock is currently owned by corporate insiders.

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of DexCom by 5,000.4% in the first quarter. BlackRock Inc. now owns 4,160,862 shares of the medical device company’s stock worth $352,550,000 after buying an additional 4,079,283 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of DexCom by 304.3% in the first quarter. Bank of New York Mellon Corp now owns 2,546,729 shares of the medical device company’s stock worth $215,785,000 after buying an additional 1,916,759 shares during the last quarter. Janus Capital Management LLC raised its stake in shares of DexCom by 99.7% in the fourth quarter. Janus Capital Management LLC now owns 3,565,809 shares of the medical device company’s stock worth $213,021,000 after buying an additional 1,779,973 shares during the last quarter. Brown Advisory Inc. raised its stake in shares of DexCom by 31.1% in the fourth quarter. Brown Advisory Inc. now owns 4,797,406 shares of the medical device company’s stock worth $286,406,000 after buying an additional 1,138,100 shares during the last quarter. Finally, FMR LLC raised its stake in shares of DexCom by 9.1% in the first quarter. FMR LLC now owns 9,845,408 shares of the medical device company’s stock worth $834,201,000 after buying an additional 823,406 shares during the last quarter.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

12 Month Chart for NASDAQ:DXCM

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.